Published in BMJ Clin Evid on October 01, 2009
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol (2017) 1.11
Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA (2004) 6.96
Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet (2002) 5.58
Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut (2001) 4.97
Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med (1998) 4.66
Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology (1997) 4.59
Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst (2000) 4.51
Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet (1997) 3.67
Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst (2006) 3.36
Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med (2001) 3.02
The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology (1999) 2.64
Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut (2006) 2.56
Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet (2002) 2.52
Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial. Lancet (2000) 2.19
Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology (2005) 2.07
Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med (1999) 1.88
Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol (1998) 1.73
The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment Pharmacol Ther (1999) 1.57
Efficacy and safety of Helicobacter pylori eradication therapy with omeprazole, amoxicillin and high- and low-dose clarithromycin in Japanese patients: a randomised, double-blind, multicentre study. Clin Drug Investig (2006) 1.51
Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology (2001) 1.50
A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther (2000) 1.36
Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther (2000) 1.33
Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther (2003) 1.14
High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther (2002) 1.10
2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study. Helicobacter (2006) 1.10
Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther (2003) 1.08
Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol (1997) 1.08
Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy. J Formos Med Assoc (2000) 1.07
Sequential regimens for Helicobacter pylori eradication. Lancet (2007) 1.05
Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter (2007) 1.02
Helicobacter pylori infection. J Antimicrob Chemother (1993) 1.01
A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori. Digestion (2006) 1.00
Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther (2004) 0.99
Can therapy even be denied for Helicobacter pylori infection? Gastroenterology (1997) 0.97
Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther (2003) 0.96
Relationship between the birth cohort pattern of Helicobacter pylori infection and the epidemiology of duodenal ulcer. QJM (2002) 0.95
Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. Aliment Pharmacol Ther (2003) 0.95
Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. Aliment Pharmacol Ther (2002) 0.94
Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther (1999) 0.94
Triple vs quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. Aliment Pharmacol Ther (2003) 0.89
Host determinants of Helicobacter pylori infection and its clinical outcome. Helicobacter (1999) 0.87
Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication. Aliment Pharmacol Ther (2003) 0.84
Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. Aliment Pharmacol Ther (2000) 0.84
Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol (2004) 0.82
Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains. Aliment Pharmacol Ther (1999) 0.82
Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori. Turk J Gastroenterol (2004) 0.82
Comparison between empirical prokinetics, Helicobacter test-and-treat and empirical endoscopy in primary-care patients presenting with dyspepsia: a one-year study. World J Gastroenterol (2006) 0.81
Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication. Aliment Pharmacol Ther (2005) 0.81
Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study. Aliment Pharmacol Ther (1998) 0.79
[Diagnosis and treatment of Helicobacter pylori infection. Its relationship with gastrointestinal ulcer and antimicrobial resistance]. Medicina (B Aires) (2001) 0.79
Helicobacter pylori in the upper gastrointestinal tract: medical or surgical treatment of gastric lymphoma? Langenbecks Arch Surg (2000) 0.79
Economic evaluation of empirical antisecretory therapy versus Helicobacter pylori test for management of dyspepsia: a randomized trial in primary care. Int J Technol Assess Health Care (2006) 0.78
Helicobacter pylori eradication in long-term proton pump inhibitor users in primary care: a randomized controlled trial. Aliment Pharmacol Ther (2007) 0.76
[Eradication effect of lansoprazole-based triple therapy against H. pylori]. Nihon Rinsho (2004) 0.75
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut (2013) 4.29
Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol (2007) 4.14
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ (2008) 4.12
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 3.97
Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology (2010) 3.32
Effect of comorbidity on mortality in patients with peptic ulcer bleeding: systematic review and meta-analysis. Am J Gastroenterol (2013) 2.97
Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA (2008) 2.89
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol (2005) 2.56
Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev (2013) 2.53
Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am J Gastroenterol (2008) 2.52
Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev (2010) 2.47
Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology (2006) 2.46
American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology (2005) 2.39
Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol (2005) 2.36
Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut (2010) 2.21
Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology (2013) 2.13
Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology (2005) 2.07
Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 2.04
Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol (2008) 2.02
Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med (2013) 2.01
Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol (2007) 2.00
EUS: a meta-analysis of test performance in suspected choledocholithiasis. Gastrointest Endosc (2008) 1.85
Ulcerative colitis. BMJ (2013) 1.76
Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol (2009) 1.67
Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.60
Symptom-based outcome measures for dyspepsia and GERD trials: a systematic review. Am J Gastroenterol (2005) 1.59
Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. Gastroenterology (2010) 1.58
Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev (2015) 1.58
Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev (2007) 1.57
Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst (2004) 1.54
Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med (2009) 1.53
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol (2010) 1.50
Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature. PLoS One (2012) 1.48
Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol (2004) 1.47
Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol (2008) 1.44
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol (2011) 1.42
Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol (2013) 1.41
Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol (2005) 1.40
Acid-suppressive therapy with esomeprazole for relief of unexplained chest pain in primary care: a randomized, double-blind, placebo-controlled trial. Am J Gastroenterol (2012) 1.40
Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol (2009) 1.39
Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology (2002) 1.36
Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol (2009) 1.29
Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol (2005) 1.28
Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 1.24
Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents--an evidence-based evaluation. Can J Gastroenterol (2005) 1.17
Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol (2009) 1.16
Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.14
How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol (2003) 1.12
Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study. Am J Gastroenterol (2007) 1.11
Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics. Contemp Clin Trials (2012) 1.10
Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.10
What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol (2010) 1.10
Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. Gut (2006) 1.08
Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment. Can J Gastroenterol (2007) 1.07
Rates of upper gastrointestinal endoscopy and gastro-oesophageal malignancy outcomes. Gut (2013) 1.05
Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol (2008) 1.04
A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial. Gastroenterology (2005) 1.02
Effect of dyspepsia on survival: a longitudinal 10-year follow-up study. Am J Gastroenterol (2012) 1.02
Peripheral mechanisms in irritable bowel syndrome. N Engl J Med (2013) 1.01
Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol (2008) 0.97
Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol (2011) 0.96
Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn? Am J Gastroenterol (2009) 0.95
Randomized controlled trial comparing telephone and mail follow-up for recruitment of participants into a clinical trial of colorectal cancer screening. Trials (2013) 0.93
Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile: antibiotics alone or combined antibiotics/immunomodulators? Inflamm Bowel Dis (2010) 0.93
Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. Am J Gastroenterol (2011) 0.93
Does long term aspirin prevent cancer? BMJ (2010) 0.91
Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. Scand J Gastroenterol (2015) 0.89
Stress ulcer prophylaxis in critically ill patients: review of the evidence. Pol Arch Med Wewn (2012) 0.89
A systematic review of psychological therapies for nonulcer dyspepsia. Am J Gastroenterol (2004) 0.89
Methodology for randomized trials of patients with nonvariceal upper gastrointestinal bleeding: recommendations from an international consensus conference. Am J Gastroenterol (2009) 0.89
Effect of sibling number in the household and birth order on prevalence of Helicobacter pylori: a cross-sectional study. Int J Epidemiol (2007) 0.87
Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol (2002) 0.86
Guidewire-assisted cannulation of the common bile duct for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. Cochrane Database Syst Rev (2012) 0.85
Addendum: BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol (2015) 0.84
WITHDRAWN: Initial management strategies for dyspepsia. Cochrane Database Syst Rev (2009) 0.84
Effectiveness of disseminating consensus management recommendations for ulcer bleeding: a cluster randomized trial. CMAJ (2013) 0.84
Eradicating H pylori. BMJ (2004) 0.83
Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome. Am J Gastroenterol (2009) 0.83
Hip fracture and proton pump inhibitor therapy: position statement. Can J Gastroenterol (2008) 0.83
Colorectal cancer screening with fecal occult blood testing (FOBT): an international perspective. Am J Gastroenterol (2006) 0.83
Managing dyspepsia. Curr Gastroenterol Rep (2009) 0.83
Current guidelines for dyspepsia management. Dig Dis (2008) 0.82
Proton pump inhibitors and risk of bone fractures. Curr Treat Options Gastroenterol (2014) 0.82
Redundant data in the meta-analysis on Helicobacter pylori eradication. Ann Intern Med (2009) 0.82
WITHDRAWN: Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev (2010) 0.80
Barrett's esophagus and obesity: the missing part of the puzzle. Am J Gastroenterol (2008) 0.80
Non-erosive reflux disease--defining the entity and delineating the management. Digestion (2008) 0.80
A validation study of the Italian Short-Form Leeds Dyspepsia Questionnaire. Intern Emerg Med (2010) 0.79
The promises and perils of nurse-led flexible sigmoidoscopy screening. Can J Gastroenterol (2007) 0.78
A glossary of economic terms. Eur J Gastroenterol Hepatol (2004) 0.78
Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum (2009) 0.78
Is it safe to use a proton pump inhibitor with clopidogrel? Pol Arch Med Wewn (2009) 0.78
Proton pump inhibitors and clopidogrel - hazardous drug interaction or hazardous interpretation of data? Can J Gastroenterol (2009) 0.78
A second-order simulation model of the cost-effectiveness of managing dyspepsia in the United States. Med Decis Making (2007) 0.78
Endoscopic screening and surveillance for Barrett's esophagus--clinical implications. MedGenMed (2006) 0.78
Does aspirin really reduce the risk of colon cancer? Lancet (2012) 0.78
Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol (2011) 0.77